Weekly Digest – August 2025 Weekly Digest – August 2025 29 July 2025: Alphamab Oncology announces anti-HER2 biparatopic ADC JSKN003 obtained orphan drug designation from the U.S. FDA for the treatment of GC/GEJ Alphamab Oncology’s anti-HER2 biparatopic ADC, JSKN003, received […]
Weekly Digest – August 2025 Weekly Digest – August 2025 28 July 2025: Zymeworks announces FDA clearance of investigational new drug application for ZW251, a novel glypican 3-targeted topoisomerase I inhibitor antibody-drug conjugate Zymeworks received FDA IND clearance for ZW251, […]
Weekly Digest – August 2025 Weekly Digest – August 2025 27 July 2025: Chong Kun Dang’s ADC-based anticancer drug receives FDA approval for Phase 1/2 clinical trials Chong Kun Dang secures FDA nod to launch U.S. Phase 1/2 trials for […]
Weekly Digest – August 2025 Weekly Digest – August 2025 28 July 2025: ESMO 2025, CStone Pharmaceuticals to disclose CS5001 ADC updated study design for the first time The Phase 1 global, multicenter trial of CS5001 is currently ongoing in the U.S., […]
Weekly Digest – August 2025 Weekly Digest – August 2025 27 July 2025: JSKN003 received the U.S FDA approval to initiate a Phase 2 clinical study in the treatment of PROC not restricted by HER2 expression Alphamab Oncology received U.S. […]
Weekly Digest – August 2025 Weekly Digest – August 2025 24 July 2025: Owkin teams up with NeoGenomics and France Tissue Bank to build IHC-dedicated foundation model for AI-driven ADC diagnostics Owkin is developing an AI foundation model trained exclusively […]
